Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Weight, GLP-1 & Metabolic Therapy

CoverageWeight, GLP-1 & Metabolic Therapy

Do GLP-1 receptor agonists reduce major cardiovascular events?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·14 studies analyzed·3 core studies·Applies to: men with preexisting or high cardiovascular risk

Bottom line

GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.[1–6]

Evidence confidence

Evidence Confidence

High
LimitedModerateHigh

Multiple high-quality studies directly address this question, with generally consistent findings.

Key uncertainty. Cardiovascular benefit is agent-specific and studied mainly in high-risk type 2 diabetes or obesity populations.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

Do GLP-1 drugs reduce heart attack risk?▼

Semaglutide (SUSTAIN-6, SELECT) and liraglutide (LEADER) reduce major adverse cardiovascular events in adults with type 2 diabetes or established ASCVD. Cardiovascular benefit is agent-specific.

SELECT trial semaglutide cardiovascular▼

SELECT randomized adults with overweight or obesity and established cardiovascular disease to semaglutide 2.4 mg vs placebo and showed a 20% relative reduction in MACE, including in those without diabetes.

GLP-1 agonist heart failure benefit▼

STEP-HFpEF and related trials show semaglutide reduces symptoms and body weight in heart failure with preserved ejection fraction. Whether all GLP-1 agents share this benefit is being studied.

Do GLP-1 drugs work for cardiovascular risk without diabetes?▼

SELECT specifically enrolled people without diabetes and showed cardiovascular benefit with semaglutide. This extends GLP-1 cardiovascular evidence beyond the traditional type 2 diabetes population.

Semaglutide MACE▼

GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.

GLP-1 heart outcomes▼

GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 13 relevant studies.

Overall finding

6 studies address major adverse cardiovascular events, with weighted findings showing benefit. 2 studies address mortality, with weighted findings showing unclear findings. 7 studies address weight / body composition, with weighted findings showing benefit. 3 studies address hba1c / glycemic control, with weighted findings showing benefit. 6 randomized or systematic-review reports and 5 observational studies address treatment.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Favors treatment

Major adverse cardiovascular events

moderate · 6 studies

6 studies address major adverse cardiovascular events, with weighted findings showing benefit. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 37952131PMID 27295427PMID 38907684PMID 38740993PMID 39941615PMID 42145153
Unclear

Mortality

moderate · 2 studies

2 studies address mortality, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 27633186PMID 38907684
Favors treatment

Weight / body composition

moderate · 7 studies

7 studies address weight / body composition, with weighted findings showing benefit. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 33567185PMID 38740993PMID 42600634PMID 40537987PMID 42060800PMID 42588312PMID 41909366
Favors treatment

HbA1c / glycemic control

moderate · 3 studies

3 studies address hba1c / glycemic control, with weighted findings showing benefit. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 38907684PMID 40537987PMID 42060800
Favors treatment

Blood pressure

limited · 1 study

1 study addresses blood pressure, with weighted findings showing benefit. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 40537987
Favors treatment

LDL-C

limited · 1 study

1 study addresses ldl-c, with weighted findings showing benefit. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 40537987

Magnitude / clinical importance

Validated effect estimates in the analyzed set include hazard ratio.; or 1.0; odds ratio=1.34. Statistical significance is not the same as clinical importance.

Interpret magnitude in absolute terms for the patient in front of you, not from relative estimates alone.

Agreement across studies

Findings are mixed after weighting by design, quality, and directness.

Supports main conclusion: 2 · Neutral / mixed: 9 · Credible conflicting: 2

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the inciden…
  • In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus wa…
  • In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.
  • This meta-analysis aimed to clarify the association between glucagon-like peptide-1 receptor agonists, used for weight management in obesity, and the risks of pancreatitis and pancreatic cancer.

Risks & harms

6 studies report safety-relevant findings. Design mix: Randomized controlled trial, Study design not clearly classified, Narrative review, Expert opinion / editorial. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

The evidence set is heterogeneous. The most recurrent population is men with preexisting or high cardiovascular risk, but several distinct groups were studied.

What remains uncertain

  • Cardiovascular benefit is agent-specific and studied mainly in high-risk type 2 diabetes or obesity populations.
  • Cardiovascular benefit is agent-specific and studied mainly in high-risk type 2 diabetes or obesity populations.
  • Surrogate improvement does not prove a hard clinical outcome.

Clinical takeaway

Prioritize GLP-1 receptor agonists with proven cardiovascular benefit in high-risk type 2 diabetes or obesity when cardiometabolic risk reduction is a treatment goal. Agent selection should match labeled outcome evidence and patient comorbidity.

Favors treatment

Major adverse cardiovascular events?

Benefit

moderate[37952131 · 27295427 · 38907684 · 38740993 · 39941615 · 42145153]

Unclear

Mortality?

Unclear findings

moderate[27633186 · 38907684]

Favors treatment

Weight / body composition?

Benefit

moderate[33567185 · 38740993 · 42600634 · 40537987 · 42060800 · 42588312 · 41909366]

Favors treatment

HbA1c / glycemic control?

Benefit

moderate[38907684 · 40537987 · 42060800]

Favors treatment

Blood pressure?

Benefit

limited[40537987]

Favors treatment

LDL-C?

Benefit

limited[40537987]

Unclear

Bone mineral density?

Unclear findings

limited[42588312]

6 randomized or systematic-review reports and 5 observational studies address treatment. Weighted treatment findings show benefit.

6 RCT / systematic review · 5 observational

Large randomized trials strongly influence the conclusion

3 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

11 supporting studies add context beyond the core evidence base.

Regimen & duration

Observational and supporting studies provide context and do not outrank higher-appropriateness designs.

Long-term uncertainty

Evidence beyond long follow-up windows and in certain subgroups remains less complete.

13 analyzed studies

Strongest evidence

The New England journal of medicine2023

Landmark studyPMID 37952131

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 m…

RCT
Evidence
Relevance
The New England journal of medicine2016

Landmark studyPMID 27295427

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER Clinic…

RCT
Evidence
Relevance
The New England journal of medicine2016

Landmark studyPMID 27633186

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide. (Fund…

RCT
Evidence
Relevance

Supporting literature

Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.

+8 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Weight, GLP-1 & Metabolic Therapy.

Does GLP-1 treatment cause meaningful muscle loss?

GLP-1 therapies reduce weight through fat and lean mass loss; lean loss is partly proportional to total weight lost. Resistance training and adequate protein may mitigate but not eliminate lean mass decline.

11 linked studies

Do patients regain weight after stopping GLP-1 therapy?

Clinical trials and observational follow-up show substantial weight regain after GLP-1 discontinuation, suggesting chronic therapy may be needed to maintain benefit unless durable lifestyle changes are established.

11 linked studies

Do GLP-1 agonists increase pancreatitis risk?

Early signals raised pancreatitis concern, but large trials and post-marketing data have not confirmed a strong causal increase at population level. Caution remains reasonable in patients with prior pancreatitis.

11 linked studies

Do GLP-1 drugs increase thyroid cancer risk in humans?

Rodent C-cell tumor signals led to contraindications in medullary thyroid carcinoma and MEN2. Human epidemiologic data have not established a clear excess of thyroid cancer, but long-term surveillance continues.

11 linked studies

Go deeper on Weight, GLP-1 & Metabolic Therapy

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Weight, GLP-1 & Metabolic TherapyView pricing